bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript

Julie Overton
Director of Communications

Everyone, thank you for joining us tonight for our CyPath Lung in Practice webinar. My name is Julie Anne Overton, and I’m the Director of Communications here at bioAffinity Technologies.

Before we begin the webinar, I have a few housekeeping items to go over. The session is being recorded and will be available for viewing on our website at www.cypathlung.com. Regarding tonight setup, all of the attendees are muted by default and your cameras will remain off throughout the session. Dr. Gordon Downie, who is our Chief Medical Officer here at bioAffinity Technologies, is going to moderate the conversation and he will introduce our panel of pulmonologists. You may submit a written question at any point during the webinar through the Q&A panel at the bottom of your screen. Dr. Downie will direct the questions to our panelists during our question-and-answer periods throughout the program. And if we don’t get to all the questions, we’re going to try to follow up with an e-mail after the fact.

For our healthcare professionals who are joining us tonight, you will receive your DoorDash voucher on the same e-mail that you used to register for the webinar.

With that, I’m going to hand things over to Dr. Downie and our panel of physicians. Thank you again for being here.

Gordon Downie
Chief Medical Officer

Thank you, Julie Anne. My name is Dr. Gordon Downie. I welcome you to the audience tonight for our CyPath Lung Testing, a simpler path forward. I’d like to thank bioAffinity